{
    "clinical_study": {
        "@rank": "139395", 
        "arm_group": [
            {
                "arm_group_label": "N-acetylcysteine", 
                "arm_group_type": "Experimental", 
                "description": "N-acetylcysteine bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs"
            }, 
            {
                "arm_group_label": "Glucose 5%", 
                "arm_group_type": "Placebo Comparator", 
                "description": "equivalent volume over the same period."
            }
        ], 
        "brief_summary": {
            "textblock": "We aim to investigate the efficacy of N-acetylcysteine (NAC) to attenuate acute renal\n      dysfunction in patients with rheumatic valvular heart disease undergoing single valve\n      replacement."
        }, 
        "brief_title": "N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Cardiac Surgery for Rheumatic Valvular Heart Disease", 
            "Renal Dysfunction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Diseases", 
                "Heart Valve Diseases", 
                "Rheumatic Diseases", 
                "Rheumatic Heart Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with rheumatic heart disease undergoing single valve replacement\n\n        Exclusion Criteria:\n\n          -  End stage renal disease (plasma creatinine concentration \u2265 300 \u00b5mol/L)\n\n          -  Emergency cardiac surgery\n\n          -  Planned off-pump cardiac surgery\n\n          -  Chronic inflammatory disease on immunosuppression\n\n          -  Chronic moderate to high dose corticosteroid therapy (\u2265 10 mg/day prednisone or\n             equivalent)\n\n          -  Age \u2264 18 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01704482", 
            "org_study_id": "tafanono01003060187"
        }, 
        "intervention": [
            {
                "arm_group_label": "N-acetylcysteine", 
                "description": "NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs", 
                "intervention_name": "N-acetylcysteine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Glucose 5%", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcysteine", 
                "N-monoacetylcystine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 10, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Assiut", 
                    "country": "Egypt", 
                    "zip": "11111"
                }, 
                "name": "Assiut University hospital"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement.", 
        "other_outcome": {
            "measure": "the urinary output", 
            "safety_issue": "No", 
            "time_frame": "the first five postoperative days"
        }, 
        "overall_official": [
            {
                "affiliation": "Assiut university hosiptal", 
                "last_name": "Laila H Mohamed, Prof", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Assiut university hosiptal", 
                "last_name": "Nawal A Gad El-rab, Prof", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Assiut university hosiptal", 
                "last_name": "Fatma A Abd El-Aal, Ass Prof", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Absolute change in serum creatinine from baseline to peak level", 
            "safety_issue": "No", 
            "time_frame": "within 5 days after surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01704482"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Assiut University", 
            "investigator_full_name": "Mostafa Samy Abbas", 
            "investigator_title": "assistant lecturer of anesthesia and ICU, Assiut University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "the relative change in serum creatinine.", 
            "safety_issue": "No", 
            "time_frame": "the first five postoperative days"
        }, 
        "source": "Assiut University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assiut University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}